Dominika DołęGa-Mostowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominika DołęGa-Mostowska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Buczkowska
Clinical Hospital of Poznan University of Medical Sciences, Poland
5 shared publications - Julia Danieluk
Day Surgery Department, Clinical Hospital of Poznań University of Medical Sciences, Poznań, Poland
5 shared publications - Julia Sochowska
Clinical Hospital of Poznan University of Medical Sciences, Poland
5 shared publications - Justyna Wójcik
Clinical Hospital of Poznan University of Medical Sciences, Poland
5 shared publications - Laura Stochaj
Department of Invasive Cardiology and Internal Medicine with the Intensive Cardiac Care Unit, Provincial Hospital in Poznań, Poznań, Poland
5 shared publications - Michalina Flejszman
Faculty of Medicine, Poznan University of Medical Sciences, Poznań, Poland
5 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Medical Communications Sp. z.o.o. in Aktualności Neurologiczne
- Vol. 26 (2) , 60
Anti-NMDAR encephalitis in children: a psychiatric or neurological disorder? Impact of delayed diagnosis and treatment on cognitive recovery – a narrative review (2020–2026)
Objective: This review synthesises the literature on paediatric anti-NMDAR encephalitis, focusing on the overlap between psychiatric and neurological symptoms and the impact of delayed diagnosis and treatment on cognitive recovery. Methods: A narrative review (2020 – April 2026) of the PubMed and Google Scholar databases was conducted, focusing on paediatric populations, treatment timing, and cognitive outcomes. Main results: In paediatric cohorts, psychiatric symptoms appear at disease onset in 80% of cases, though purely psychiatric presentations are rare. Because the disease mimics primary psychosis, 40% of patients are initially admitted to psychiatric wards, resulting in significant delays. Misdiagnosis poses a risk of life-threatening neuroleptic malignant syndrome in 12% of patients receiving antipsychotic medication. Initiation of immunotherapy within four weeks is a major modifiable factor associated with successful functional recovery (modified Rankin Scale, mRS 0–2). Delays exceeding 30 days are linked to a higher risk of persistent cognitive impairments, including memory and executive dysfunction, although prognosis is inherently multifactorial and influenced by disease severity and age. Long-term trajectories show complete remission in 73% of patients, isolated deficits in 18%, and multidomain impairment in 9%. Onset before the age of six is a critical vulnerability; 35% of these children remain dependent on social and family support a decade post-diagnosis. Conclusion: Paediatric anti-NMDAR encephalitis blurs the boundaries between neurology and psychiatry. Clinicians should actively identify neurological “red flags” to prevent misdiagnosis. Prompt multidisciplinary care and initiation of immunotherapy within four weeks help minimise cognitive deficits, prevent long-term dependency, and support restoration of the child’s normal neurodevelopmental trajectory, although final outcomes depend on clinical, radiological, and demographic factors.
- 5 October 2026
- Published by Medical Communications Sp. z.o.o. in Aktualności Neurologiczne
- Vol. 26 (2) , 60
Open AccessAnti-NMDAR encephalitis in children: a psychiatric or neurological disorder? Impact of delayed diagnosis and treatment on cognitive recovery – a narrative review (2020–2026)
Objective: This review synthesises the literature on paediatric anti-NMDAR encephalitis, focusing on the overlap between psychiatric and neurological symptoms and the impact of delayed diagnosis and treatment on cognitive recovery. Methods: A narrative review (2020 – April 2026) of the PubMed and Google Scholar databases was conducted, focusing on paediatric populations, treatment timing, and cognitive outcomes. Main results: In paediatric cohorts, psychiatric symptoms appear at disease onset in 80% of cases, though purely psychiatric presentations are rare. Because the disease mimics primary psychosis, 40% of patients are initially admitted to psychiatric wards, resulting in significant delays. Misdiagnosis poses a risk of life-threatening neuroleptic malignant syndrome in 12% of patients receiving antipsychotic medication. Initiation of immunotherapy within four weeks is a major modifiable factor associated with successful functional recovery (modified Rankin Scale, mRS 0–2). Delays exceeding 30 days are linked to a higher risk of persistent cognitive impairments, including memory and executive dysfunction, although prognosis is inherently multifactorial and influenced by disease severity and age. Long-term trajectories show complete remission in 73% of patients, isolated deficits in 18%, and multidomain impairment in 9%. Onset before the age of six is a critical vulnerability; 35% of these children remain dependent on social and family support a decade post-diagnosis. Conclusion: Paediatric anti-NMDAR encephalitis blurs the boundaries between neurology and psychiatry. Clinicians should actively identify neurological “red flags” to prevent misdiagnosis. Prompt multidisciplinary care and initiation of immunotherapy within four weeks help minimise cognitive deficits, prevent long-term dependency, and support restoration of the child’s normal neurodevelopmental trajectory, although final outcomes depend on clinical, radiological, and demographic factors.
- Open Access
- 4 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
THE IMPACT OF CREATINE SUPPLEMENTATION AND HIGH-PROTEIN DIET ON KIDNEY FUNCTION IN PHYSICALLY ACTIVE INDIVIDUALS: A NARRATIVE REVIEW
The safety of high-protein diets (HPD) and creatine supplementation remains a central topic of debate between the sports nutrition and nephrology communities. While athletes utilize these strategies to optimize body composition and performance, concerns regarding renal health, specifically glomerular hyperfiltration and the interpretation of creatinine-based biomarkers, persist. This narrative review synthesizes evidence from randomized controlled trials, systematic reviews and meta-analyses, observational studies, mechanistic studies, and clinical guidelines. Current evidence suggests that in healthy, physically active individuals, neither creatine supplementation at recommended doses nor high protein diet (up to 3.4 g/kg/d) negatively affect renal function. However, the interpretation of serum creatinine in active populations is often harder to interpret accurately by higher muscle metabolism and creatine supplementation. While nephrology literature highlights potential risks of high protein diet in individuals with pre-existing chronic kidney disease, these findings may not be directly generalizable to the healthy population. Studies regarding both creatine supplementation and HPD in healthy individuals at the same time are limited and need further research.
- 4 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessTHE IMPACT OF CREATINE SUPPLEMENTATION AND HIGH-PROTEIN DIET ON KIDNEY FUNCTION IN PHYSICALLY ACTIVE INDIVIDUALS: A NARRATIVE REVIEW
The safety of high-protein diets (HPD) and creatine supplementation remains a central topic of debate between the sports nutrition and nephrology communities. While athletes utilize these strategies to optimize body composition and performance, concerns regarding renal health, specifically glomerular hyperfiltration and the interpretation of creatinine-based biomarkers, persist. This narrative review synthesizes evidence from randomized controlled trials, systematic reviews and meta-analyses, observational studies, mechanistic studies, and clinical guidelines. Current evidence suggests that in healthy, physically active individuals, neither creatine supplementation at recommended doses nor high protein diet (up to 3.4 g/kg/d) negatively affect renal function. However, the interpretation of serum creatinine in active populations is often harder to interpret accurately by higher muscle metabolism and creatine supplementation. While nephrology literature highlights potential risks of high protein diet in individuals with pre-existing chronic kidney disease, these findings may not be directly generalizable to the healthy population. Studies regarding both creatine supplementation and HPD in healthy individuals at the same time are limited and need further research.
- Open Access
- 14 July 2026
- Published by National Institute of Public Health NIH (National Research Institute) in Roczniki Panstwowego Zakladu Higieny
- Vol. 77 (1) , 33-41
Ketogenic diet in adult obesity: safety, limitations, and evidence from various clinical applications
The aim of this study was to present the current state of knowledge regarding the use of the ketogenic diet in the treatment of obesity in adults, with particular emphasis on its safety, indications, and contraindications, and to relate these findings to its established use in drug-resistant epilepsy and other clinical conditions. Despite growing interest in its clinical application, the effectiveness and safety of this intervention remain a matter of debate. A narrative review of the literature available in PubMed and Google Scholar from 2021 to 2024 was conducted using the keywords “ketogenic diet,” “obesity,” “epilepsy,” “type 2 diabetes,” “cardiovascular diseases,” “PCOS,” “neurological diseases,” and “psychiatric disorders,” as well as their combinations with AND/OR operators. Meta-analyses, randomized controlled trials, systematic reviews, and selected clinical trials evaluating the effectiveness and safety of the ketogenic diet were included in the analysis. The ketogenic diet demonstrates effectiveness in short-term weight loss and improvement of selected metabolic parameters in patients with obesity. However, its long-term effects remain equivocal and do not appear to offer significant advantages over other dietary strategies. The diet is associated with a risk of adverse effects and requires appropriate clinical monitoring. While it is a recognized and effective therapeutic option for drug-resistant epilepsy, its use in other conditions has not been established as a standard therapeutic approach. The ketogenic diet may be considered as part of obesity treatment in carefully selected patients, provided that potential benefits and risks are individually assessed. Further high-quality studies are needed to determine its long-term effectiveness and safety.
- 14 July 2026
- Published by National Institute of Public Health NIH (National Research Institute) in Roczniki Panstwowego Zakladu Higieny
- Vol. 77 (1) , 33-41
Open AccessKetogenic diet in adult obesity: safety, limitations, and evidence from various clinical applications
The aim of this study was to present the current state of knowledge regarding the use of the ketogenic diet in the treatment of obesity in adults, with particular emphasis on its safety, indications, and contraindications, and to relate these findings to its established use in drug-resistant epilepsy and other clinical conditions. Despite growing interest in its clinical application, the effectiveness and safety of this intervention remain a matter of debate. A narrative review of the literature available in PubMed and Google Scholar from 2021 to 2024 was conducted using the keywords “ketogenic diet,” “obesity,” “epilepsy,” “type 2 diabetes,” “cardiovascular diseases,” “PCOS,” “neurological diseases,” and “psychiatric disorders,” as well as their combinations with AND/OR operators. Meta-analyses, randomized controlled trials, systematic reviews, and selected clinical trials evaluating the effectiveness and safety of the ketogenic diet were included in the analysis. The ketogenic diet demonstrates effectiveness in short-term weight loss and improvement of selected metabolic parameters in patients with obesity. However, its long-term effects remain equivocal and do not appear to offer significant advantages over other dietary strategies. The diet is associated with a risk of adverse effects and requires appropriate clinical monitoring. While it is a recognized and effective therapeutic option for drug-resistant epilepsy, its use in other conditions has not been established as a standard therapeutic approach. The ketogenic diet may be considered as part of obesity treatment in carefully selected patients, provided that potential benefits and risks are individually assessed. Further high-quality studies are needed to determine its long-term effectiveness and safety.
- Open Access
- 9 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 62, 73136
Continuous Glucose Monitoring (CGM) in Long-Distance Runners: A Narrative Review of Performance Optimization and Hypoglycemia Prevention.
Background. Continuous Glucose Monitoring (CGM) is increasingly used by ultra-endurance athletes to refine complex fueling strategies. However, transitioning this clinical tool into a performance monitoring remains difficult, largely due to the interstitial-to-blood lag time that can distort real-time data interpretation. Aim. This study aims to synthesize current literature to evaluate the application of CGM data during extreme exercise, examining how exercise intensity, dietary protocols, and technical artifacts influence metabolic data interpretation and fueling efficacy. Material and Methods. A review of literature was performed with a primary focus on literature from 2020 to 2026, while including foundational technical research. The analysis examined the impact of a broad range of physical and technical factors on the practical application and limitations of CGM. Results. CGM accuracy, measured by MARD, often drops during high-intensity exercise and dehydration. There are clear differences between interstitial readings and blood glucose levels that athletes must account for. Data integrity is affected by factors like thermal stress, caffeine intake, and localized tissue compression. Findings also show that metabolic responses to CGM vary depending on sex and dietary status, such as LCHF. While the technology helps track carbohydrate absorption during 120 g/h protocols, it can also mask a systemic energy deficit if the athlete relies only on stable readings. Sensor lag remains a critical issue, where glucose levels on the screen do not always reflect actual glycogen availability or energy status. Conclusions. To improve performance, athletes should focus on trend arrows rather than static numbers. CGM is a monitoring tool, not an absolute source of physiological truth. Using a structured protocol helps manage sensor lag and prevents metabolic crashes. This approach makes it easier to stay on track with fueling and pacing during extreme effort.
- 9 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 62, 73136
Open AccessContinuous Glucose Monitoring (CGM) in Long-Distance Runners: A Narrative Review of Performance Optimization and Hypoglycemia Prevention.
Background. Continuous Glucose Monitoring (CGM) is increasingly used by ultra-endurance athletes to refine complex fueling strategies. However, transitioning this clinical tool into a performance monitoring remains difficult, largely due to the interstitial-to-blood lag time that can distort real-time data interpretation. Aim. This study aims to synthesize current literature to evaluate the application of CGM data during extreme exercise, examining how exercise intensity, dietary protocols, and technical artifacts influence metabolic data interpretation and fueling efficacy. Material and Methods. A review of literature was performed with a primary focus on literature from 2020 to 2026, while including foundational technical research. The analysis examined the impact of a broad range of physical and technical factors on the practical application and limitations of CGM. Results. CGM accuracy, measured by MARD, often drops during high-intensity exercise and dehydration. There are clear differences between interstitial readings and blood glucose levels that athletes must account for. Data integrity is affected by factors like thermal stress, caffeine intake, and localized tissue compression. Findings also show that metabolic responses to CGM vary depending on sex and dietary status, such as LCHF. While the technology helps track carbohydrate absorption during 120 g/h protocols, it can also mask a systemic energy deficit if the athlete relies only on stable readings. Sensor lag remains a critical issue, where glucose levels on the screen do not always reflect actual glycogen availability or energy status. Conclusions. To improve performance, athletes should focus on trend arrows rather than static numbers. CGM is a monitoring tool, not an absolute source of physiological truth. Using a structured protocol helps manage sensor lag and prevents metabolic crashes. This approach makes it easier to stay on track with fueling and pacing during extreme effort.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
SMALL INTESTINAL MICROBIAL OVERGROWTH (SIBO, IMO, AND SIFO) IN THE PATHOGENESIS AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME
Background. Irritable Bowel Syndrome (IBS) is a complex functional disorder characterized by abdominal pain and altered bowel habits. Small Intestinal Bacterial Overgrowth (SIBO) is increasingly recognized as a key pathogenetic factor, shifting the understanding of IBS toward a micro-organic basis. IBS is viewed as a heterogeneous condition with distinct phenotypes: microbiota-driven, post-infectious (PI-IBS), centrally mediated, and genetic variants. Aim. To evaluate the role of SIBO, Intestinal Methanogen Overgrowth (IMO), and Small Intestinal Fungal Overgrowth (SIFO) in IBS pathogenesis, focusing on prevalence, mechanisms, and targeted therapy. Material and methods. A literature review was performed using PubMed and Scopus (2000 - 2025). The analysis included 45 sources, including meta-analyses, systematic reviews, and clinical guidelines (Rome IV, Polish Society of Gastroenterology). Results. Meta-analyses indicate that IBS patients are nearly five times more likely to test positive for SIBO than healthy individuals (OR 4.7). Hydrogen-producing bacteria are linked to diarrhea (IBS-D), while methane delays transit, correlating with constipation (IBS-C). Proposed mechanisms include excessive fermentation gas, bile acid deconjugation, and increased intestinal permeability. SIFO is found in 25% of refractory cases. Targeted eradication particularly with rifaximin achieves symptom resolution, with 48% of treated patients no longer meeting Rome criteria. However, diagnostic inconsistencies in breath tests remain a subject of clinical controversy. Conclusions. SIBO and IMO represent treatable pathomechanisms in a subset of IBS patients, supporting a transition to personalized, mechanism-based management. Identifying these phenotypes is essential for optimizing targeted antimicrobial and prokinetic therapy. Individualized diagnostics are crucial for managing the micro-organic subtype of this complex syndrome.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessSMALL INTESTINAL MICROBIAL OVERGROWTH (SIBO, IMO, AND SIFO) IN THE PATHOGENESIS AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME
Background. Irritable Bowel Syndrome (IBS) is a complex functional disorder characterized by abdominal pain and altered bowel habits. Small Intestinal Bacterial Overgrowth (SIBO) is increasingly recognized as a key pathogenetic factor, shifting the understanding of IBS toward a micro-organic basis. IBS is viewed as a heterogeneous condition with distinct phenotypes: microbiota-driven, post-infectious (PI-IBS), centrally mediated, and genetic variants. Aim. To evaluate the role of SIBO, Intestinal Methanogen Overgrowth (IMO), and Small Intestinal Fungal Overgrowth (SIFO) in IBS pathogenesis, focusing on prevalence, mechanisms, and targeted therapy. Material and methods. A literature review was performed using PubMed and Scopus (2000 - 2025). The analysis included 45 sources, including meta-analyses, systematic reviews, and clinical guidelines (Rome IV, Polish Society of Gastroenterology). Results. Meta-analyses indicate that IBS patients are nearly five times more likely to test positive for SIBO than healthy individuals (OR 4.7). Hydrogen-producing bacteria are linked to diarrhea (IBS-D), while methane delays transit, correlating with constipation (IBS-C). Proposed mechanisms include excessive fermentation gas, bile acid deconjugation, and increased intestinal permeability. SIFO is found in 25% of refractory cases. Targeted eradication particularly with rifaximin achieves symptom resolution, with 48% of treated patients no longer meeting Rome criteria. However, diagnostic inconsistencies in breath tests remain a subject of clinical controversy. Conclusions. SIBO and IMO represent treatable pathomechanisms in a subset of IBS patients, supporting a transition to personalized, mechanism-based management. Identifying these phenotypes is essential for optimizing targeted antimicrobial and prokinetic therapy. Individualized diagnostics are crucial for managing the micro-organic subtype of this complex syndrome.